Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute Myelogenous Leukemia with Hematopoietic Stem Cell Transplantation?

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 80-88

  Yoon, Jae Ho ^a   Kim, Hee Je ^a   Shin, Seung Hwan ^a   Lee, Sung Eun ^a   Cho, Byung Sik ^a   Eom, Ki Seong ^a   Kim, Yoo Jin ^a   Lee, Seok ^a   Min, Chang Ki ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Park, Chong Won ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute myelogenous leukemia; Adverse risk; Chromosomal aberration; Monosomal karyotype; Mosaicism

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ENOCITABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MELPHALAN; MITOXANTRONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME ABERRATION; CONSERVATIVE TREATMENT; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENETIC RISK; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MOSAICISM; MYELOABLATIVE CONDITIONING; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; VERY ELDERLY; WHOLE BODY RADIATION; YOUNG ADULT;

ACUTE MYELOGENOUS LEUKEMIA; ADVERSE RISK; CHROMOSOMAL ABERRATION; MONOSOMAL KARYOTYPE; MOSAICISM;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RESEARCH DESIGN; RISK; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84890895103     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.015     Document Type: Article

References (33)

1. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
2. Schoch C., Haferlach T., Haase D., et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001, 112:118-126.
3. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
5. O'Donnell M.R., Abboud C.N., Altman J., et al. Acute myeloid leukemia. JNatl Compr Canc Netw 2012, 10:984-1021.
6. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
7. Lugthart S., Groschel S., Beverloo H.B., et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. JClin Oncol 2010, 28:3890-3898.
8. Grimwade D., Walker H., Oliver F., et al. Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998, 92:2322-2333.
9. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. JClin Oncol 2008, 26:4791-4797.
10. Medeiros B.C., Othus M., Fang M., et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010, 116:2224-2228.
11. Breems D.A., Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica 2011, 96:491-493.
12. Ahn H.K., Jang J.H., Kim K., et al. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Am J Hematol 2012, 87:37-41.
13. Estey E.H., Pierce S., Keating M.J. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica 2000, 85:246-249.
14. Xie B., Othus M., Medeiros B.C., et al. Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. Haematologica 2011, 96:631-632.
15. Yoon J.H., Kim H.J., Shin S.H., et al. Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. Int J Hematol 2013, 97:773-781.
16. ISCN 2009: an international system for human cytogenetic nomenclature 2009, Karger, Basel, Switzerland. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
17. Rollig C., Bornhauser M., Thiede C., et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. JClin Oncol 2011, 29:2758-2765.
18. Medeiros B.C., Othus M., Fang M., et al. Impact of residual normal metaphases in core binding factor acute myeloid leukemia. Cancer 2012, 118:2420-2423.
19. Park H.S., Kim D.W., Kim C.C., et al. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen-a prospective, cooperative multicenter study. Semin Hematol 1996, 33:24-29.
20. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
21. Yoon J.H., Cho B.S., Kim H.J., et al. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. Am J Hematol 2013, [ePud ahead of print]. 10.1002/ajh.23576.
22. Cho B.S., Yoon J.H., Shin S.H., et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant 2012, 18:1552-1563.
23. Kim H.J., Min W.S., Eom K.S., et al. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2004, 34:215-220.
24. Gray R.J. Aclass of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
25. Schlenk R.F., Dohner K., Mack S., et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. JClin Oncol 2010, 28:4642-4648.
26. O'Donnell M.R., Abboud C.N., Altman J., et al. Acute myeloid leukemia. JNatl Compr Canc Netw 2011, 9:280-317.
27. Haferlach C., Alpermann T., Schnittger S., et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012, 119:2122-2125.
28. Armand P., Kim H.T., Zhang M.J., et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 2012, 18:280-288.
29. Voutiadou G., Papaioannou G., Gaitatzi M., et al. Monosomal karyotype in acute myeloid leukemia defines a distinct subgroup within the adverse cytogenetic risk category. Cancer Genet 2013, 206:32-36.
30. Fang M., Storer B., Estey E., et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011, 118:1490-1494.
31. Kayser S., Zucknick M., Dohner K., et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012, 119:551-558.
32. Oran B., Dolan M., Cao Q., et al. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2011, 17:356-364.
33. Middeke J.M., Beelen D., Stadler M., et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q. Blood 2012, 120:2521-2528.